Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosciens BiopharmaCSCIF 61 Days Sales Outstanding is 68.84 as of Jun. 2026, which is 29% above its 10-year median of 53.28. GuruFocus rates CSCIF with a GF Score™ of 61/100 and a GF Value™ of $7.02 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 835 Biotechnology companies, Cosciens Biopharma ranks worse than 61.44% on this metric.
Cosciens Biopharma (OTCPK:CSCIF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Cosciens Biopharma Days Sales Outstanding Related Terms
Cosciens Biopharma Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSCIF vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Cosciens Biopharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Days Sales Outstanding falls into.
Cosciens Biopharma Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (CSCIF) has a Days Sales Outstanding of 68.84 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cosciens Biopharma and its competitors. This is 29% above median its historical median of 53.28. Over the past decade, Cosciens Biopharma's Days Sales Outstanding has ranged from 14.71 to 93.67. According to the industry distribution chart, Cosciens Biopharma ranks #513 out of 835 companies in the Biotechnology industry, placing it in the top 61.4%.
Is Cosciens Biopharma's Days Sales Outstanding too high?
Cosciens Biopharma's current Days Sales Outstanding of 68.84 is 29% above median its 10-year median of 53.28. Over the past 10 years, this metric has ranged from a low of 14.71 to a high of 93.67. The Biotechnology industry median Days Sales Outstanding is 68.95. Cosciens Biopharma's value of 68.84 is 0.2% below this industry median. Based on the distribution chart, Cosciens Biopharma ranks #513 out of 835 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #513 out of 835 companies for Days Sales Outstanding. This places Cosciens Biopharma in the lower half of its industry. The industry median Days Sales Outstanding is 68.95. Cosciens Biopharma's value of 68.84 is 0.2% below this benchmark. Historically, Cosciens Biopharma's own Days Sales Outstanding has ranged from 14.71 to 93.67 over the past decade. While the company's 10-year median is 53.28 vs. the industry median of 68.95, Cosciens Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.95, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosciens Biopharma's current Days Sales Outstanding of 68.84 is 0.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cosciens Biopharma and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current Days Sales Outstanding is 68.84, which is 29% above median its own 10-year median of 53.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.02, compared to a current price of $5.50 — trading 21.7% below its estimated fair value. The current Days Sales Outstanding is 68.84, which is 29% above median its 10-year median of 53.28 and 0.2% below the Biotechnology industry median of 68.95. Cosciens Biopharma's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Days Sales Outstanding is 68.84 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $5.50 is trading 21.7% below its estimated GF Value™ of $7.02.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for CSCIF:
Days Sales Outstanding: 68.84 (29% above median its 10-year median of 53.28)
GF Value™: $7.02 vs. price of $5.50 (21.7% below fair value)
Industry Position: 0.2% below the Biotechnology median (#513 of 835)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score
Get the complete analysis for CSCIF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
